Stock Price Target Updates
BTIG maintains Buy ratings while adjusting price targets across four major stocks.
Anonymous
Key Points
1
BioAge Labs is developing therapies for metabolic diseases by targeting the biology of human aging. The clinical-stage company had an estimated market capitalization of about $433.73 million and was trading at roughly 64.5 times its historical median price-to-sales ratio, highlighting valuation and cash-flow concerns.
2
ServiceNow’s business extends beyond IT service management into customer service, human-resources service delivery and security operations through its software-as-a-service model. GuruFocus gave the company a GF Score of 83 out of 100, with especially strong growth and profitability rankings.
3
AppLovin operates a vertically integrated advertising technology platform serving both advertisers and publishers, with about 80% of revenue generated by its demand-side AppDiscovery business. GuruFocus calculated a GF Value of $583.82 and a GF Score of 89 out of 100, despite BTIG’s lower price target.
4
NeOnc Technologies is developing drug-delivery approaches for central nervous system diseases, including gliomas and glioblastoma, with product candidates such as NEO100 and NEO212. The company had an estimated market capitalization of approximately $130.2 million and was trading at a high historical median price-to-sales benchmark of about 2,490.84 times.
5
ServiceNow’s broader analyst consensus remained positive: MarketBeat data cited 36 Buy ratings, three Hold ratings and two Sell ratings, producing a Moderate Buy consensus and an average target price of $144.73. The company also reported quarterly EPS of $0.90 versus the $0.86 consensus and revenue of $3.99 billion against the $3.93 billion estimate.
BTIG kept Buy ratings on four stocks spanning biotech, software and advertising tech while making mixed price adjustments this week. The firm raised BTIG's price target for ServiceNow from $150 to $170, cut AppLovin's from $408 to $396, and held steady on BioAge Labs at $40 and NeOnc Technologies at $15. The moves reflect confidence across all four names despite distinct risks ranging from pre-revenue biotech burn rates to AppLovin's slowing growth.
Insider trading patterns show divergent sentiment. BioAge Labs, ServiceNow and AppLovin saw material insider selling, while NeOnc Technologies recorded insider buying with zero sales. ServiceNow posted earnings above estimates — $0.90 EPS versus $0.86 consensus — backing BTIG's more bullish outlook on the enterprise software provider.
ServiceNow's Beat and Wall Street Enthusiasm
ServiceNow delivered quarterly earnings above consensus, posting $0.90 EPS versus the $0.86 estimate and $3.99 billion in revenue against $3.93 billion expected. BTIG responded by lifting its price target to $170, signaling confidence in the SaaS giant's IT service management, customer service and human-resources software platforms. GuruFocus gave ServiceNow a GF Score of 83 out of 100, with particularly strong marks on growth and profitability.
Broader analyst consensus backs the bullish case. MarketBeat data shows 36 Buy ratings, three Holds and two Sells, producing a Moderate Buy consensus. The average analyst price target sits at $144.73 — below BTIG's $170 call but firmly positive. Insider selling, however, suggests some caution among executives despite the operational wins.
AppLovin's Target Cut Points to Caution
BTIG lowered AppLovin's price target to $396 from $408, a 3% reduction that hints at wariness around the ad-tech platform's near-term trajectory. The company operates a vertically integrated platform serving advertisers and publishers, with about 80% of revenue coming from its demand-side AppDiscovery business. GuruFocus calculated a GF Value of $583.82 — well above the new price target — yet gave a GF Score of 89 out of 100.
The target cut carries particular weight because BTIG maintained its Buy rating despite the downgrade. Heavy insider selling at AppLovin suggests executives may be taking chips off the table. The gap between GuruFocus's GF Value and BTIG's price target flags a disconnect — either the stock is cheaper than intrinsic value or growth headwinds loom.
Early-Stage Biotech Plays Carry High Valuation Risk
BioAge Labs, a clinical-stage biotech developing therapies for metabolic disease by targeting human aging biology, trades at roughly 64.5 times its historical median price-to-sales ratio. BTIG kept its $40 price target while the company had a market cap near $433.73 million. The steep valuation multiple underscores cash-burn risk for a pre-revenue stage company. Substantial insider selling adds concern.
NeOnc Technologies, developing drug-delivery platforms for central nervous system diseases like glioblastoma, trades at an extraordinary 2,490.84 times its historical median price-to-sales ratio. BTIG maintained its $15 target on the roughly $130.2 million market-cap company. Insider buying at NeOnc — the only stock in the group with net buying — may signal internal confidence in late-stage clinical progress or pipeline catalysts.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
6
Reach
20
A
AnonymousAuthor
